Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin in Abdominal Aortic Aneurysm (MetAAA)
NCT03507413Phase 3Active, not recruiting
- Sponsor
- Medical University of Vienna
- Start
- Sep 2018
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of liquid metformin (Aspargo Labs) in abdominal aortic aneurysm (AAA) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: AAA growth (in maximum diameter) at 12 months. Started Sep 2018; status: active, not recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
abdominal aortic aneurysm (AAA)
Beyond the preview
Go deeper on NCT03507413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03507413.